The Lateral Flow Assays industry is expected to grow significantly in the near future due to the increasing demand for rapid, portable, and easy-to-use diagnostic tests. Lateral flow assays have already proven to be valuable in a variety of applications, including medical diagnostics, food safety testing, environmental monitoring, and drug testing, among others. Advances in technology and the development of new and more sensitive detection methods are likely to further improve the performance and accuracy of lateral flow assays, making them even more versatile and useful in the years to come.
The Global Lateral Flow Assays Market in terms of revenue was estimated to be worth $20.5 billion in 2022 and is poised to reach $22.6 billion by 2027, growing at a CAGR of 2.0% from 2022 to 2027. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. Increasing adoption of kits & reagents and lateral flow assay readers for infectious diseases testing, veterinary diagnostics, and drug of abuse testing, cardiac marker testing. Whereas most of lateral flow assays are having limitation of qualitative detection, lot to lot variation like factors may hinder the growth of global market during the forecast period.
Download PDF Brochure:
Key Market Players:
The prominent players in the global lateral flow assays market include Abbott Laboratories (US), Quidel Corporation (US), F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), Siemens AG (Germany), BD (US), bioMérieux SA (France), Thermo Fisher Scientific, Inc. (US), PerkinElmer Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), and Merck KGaA (Germany).
- Kits & Reagents
- Lateral Flow Readers
- Clinical Testing
- Veterinary Diagnostics
- Food Safety & Environmental Testing
- Drug Development & Quality Testing
- Sandwich Assays
- Competitive Assays
- Multiplex Detection Assays
By Sample Type
- Blood Samples
- Urine Samples
- Saliva Samples
- Other Samples
By End User
- Hospitals & Clinics
- Diagnostics Laboratories
- Home Care Settings
- Pharmaceuticals & Biotechnology Companies
- Other End User
Request Free Sample Pages:
Lateral Flow Assays Industry Dynamics:
- High prevalence of infectious diseases across the globe
- Rapidly increasing geriatric population
- Growing usage of home-based lateral flow assay devices
- Growing demand for point-of-care testing
- Need for rapid diagnostic testing for COVID-19
- Inconsistent results of lateral flow assay tests
- Evolving applications of lateral flow assays
Rising demand for lateral flow assays in the food & beverage industry
- Omicron – The new variant of concern is an opportunity for the lateral flow assays market
- Government initiatives for omicron
- Initiatives of Medical diagnostic companies for omicron
- Limited reimbursements for lateral flow assay products
- Difficulties in procuring quality raw materials for the development of lateral flow assay tests
- In October 2022, F. Hoffmann-La Roche Ltd. (Switzerland) a next-generation portfolio of SARS-CoV-2 rapid antigen test 2.01, SARS-CoV-2 Rapid Antigen Test 2.0 Nasal2, and SARS-CoV-2 Rapid Antigen Test 2.0 Nasal3
- In June 2021, Abbott Laboratories (US) received the CE approval for PanBio Rapid Antigen Self-test, opening access throughout Europe to fast, reliable COVID-19 testing
Lateral Flow Assays Market - Report Highlights:
Refinements in the segments of the lateral flow assays market
The current edition of the report consists of an updated market overview. Additional points in the market overview have been added, keeping in mind the impact of COVID-19 on the overall lateral flow assays market and economic recession impact on lateral flow assays market. Also impact of economic recession on regional market size has been considered in this edition.
Coverage of new market players in the lateral flow assays market
The new edition of the report includes profiles for Oranoxis Inc. (US), AESKU. Diagnostics Gmbh (Germany), Bio Group Medical System (Italy), Pharmact Gmbh (Germany), DIESSE Diagnostica Senese S.P.A (Italy), and Xiamen Biotime Biotechnology Co., Ltd (China).
Updated financial information/product portfolio of players
The new edition of the report provides updated financial information until 2021 for each listed company in a graphical representation as a single diagram (instead of multiple tables). This will easily help analyze the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating country/region, business segment focus in terms of the highest revenue-generating segment, and R&D investments.
Updated market developments of profiled players
Recent developments are important to understand market trends and the growth strategies adopted by players. The current edition of this report provides updated developments of profiled players from January 2019 to December 2022, indicating a continuation from the previous version. Product/services launches, approvals, and upgrades, expansions, acquisitions, agreements, partnerships, and collaborations were the principal growth strategies adopted by market players in this period.
Inquiry Before Buying:
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1-888-600-6441